ERBB2 and breast cancer: The FDA approved ribociclib in 2017, based on the MONALEESA-2 trial, in combination with an aromatase inhibitor, as an initial endocrine-based therapy for the treatment of postmenopausal women with HR+/HER2− advanced or metastatic BC.